Literature DB >> 1725796

Arteriosclerosis and antihypertensive response to calcium antagonists in end-stage renal failure.

S J Marchais1, I Boussac, A P Guerin, G Delavaux, F Metivier, G M London.   

Abstract

The relationship between the presence of arterial calcinosis and the antihypertensive response to calcium blockers was studied in 40 hypertensive patients with end-stage renal failure (ESRF) on chronic hemodialysis, before and during 16 weeks after administration of nitrendipine in monotherapy. In a double-blind, placebo-randomized study, nitrendipine reduced systolic blood pressure regardless of the presence or absence of arterial calcifications. The antihypertensive effects were significantly more pronounced in subjects with aortic calcium deposits in comparison with patients without clinical signs of arteriosclerosis (p less than 0.01). Diastolic blood pressure was significantly reduced only in patients with aortic calcifications, and remained unchanged in subjects with noncalcified aorta. Aortic pulse wave velocity decreased significantly in patients with aortic calcifications (p less than 0.001), but remained unaffected in patients with noncalcified vessels. Multivariate regression analysis showed that antihypertensive action of nitrendipine was correlated with the presence of aortic calcium deposits independently of age or baseline blood pressure levels. The results of the present study indicate that an overt arteriosclerosis as demonstrated by the presence of aortic calcifications on abdominal radiographs is a good indication for use of dihydropiridines in patients with ESRF.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1725796

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  1 in total

1.  Calcium channel blockers for people with chronic kidney disease requiring dialysis.

Authors:  George A Mugendi; Florence M Mutua; Patrizia Natale; Tonya M Esterhuizen; Giovanni Fm Strippoli
Journal:  Cochrane Database Syst Rev       Date:  2020-10-01
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.